Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 24, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) held through employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions within employee trusts and retirement plans rather than operational financial performance.
Material Changes
- Employee Share Option Plan: On January 21, 2005, the GlaxoSmithKline Employee Trust transferred 4,382 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On January 20, 2005, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,590,587 to 18,554,433. This change occurred at an average price of $45.46.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure regarding director interests arising from their participation in discretionary employee funds.
Key Facts for Investor Verification
- Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold indirect interests in shares transferred via the GSK Trust.
- Directors Dr. J-P Garnier and Dr. T Yamada hold potential interests in the US Retirement Savings Plan ADRs.
- The reduction in ADR holdings in the US Retirement Savings Plan was driven by fund movements rather than direct director sales.